Halozyme Therapeutics Inc

NASDAQ: HALO
$37.81
-$0.21 (-0.6%)
Closing price April 18, 2024
Halozyme Therapeutics Inc is a biopharmaceutical company that specializes in developing and commercializing innovative enzyme-based therapies. Utilizing its patented recombinant human hyaluronidase enzyme (rHuPH20), Halozyme enhances the delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Its product lineup addresses a variety of medical conditions, from hydration and drug dispersion to treating chronic diseases such as HIV, multiple sclerosis, and various cancers. Founded in 1998, Halozyme is headquartered in San Diego, California, serving a global market.
Source: Jon OggThese are some of this Thursday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research calls.American Eagle Outfitters, Inc. (NYSE: AEO) Raised to...
Today was a day of red that went to a day of green.  Earnings were at first a disappointment, and producer price index came out far hotter at +0.8% on the headline number before the +0.2% reading if...
Biotech is about to become even less of a diversified sector due to mergers and acquisitions. Genzyme Corporation (NASDAQ: GENZ) and Cephalon Inc. (NASDAQ: CEPH) will end up accounting for about $30...
Thursday’s edition of the BioHealth Business Daily has many common companies through the biotech and pharma sectors, as well as some widely unknown names.  We are seeing news reactions in shares...
Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth coverage and analysis today at the website BioHealthInvestor.com: Rigel Pharmaceuticals...
Here are some of the top stories affecting key drug and biotech stocks that are covered in-depth today at BioHealthInvestor.com: Cigna corp. (NYSE: CI), Aetna Inc. (NYSE: AET), and other managed care...
Alnylam (Nasdaq: ALNY) leads a short list of some of the fastest-growing biotech stocks where analyst estimate revisions continue to rise. BioHealth Investor began by analyzing 171 stocks in the...
There are lots of names moving in biotech and related fields today, and below are some of the top movers: Anika Therapeutics Inc. (NASDAQ: ANIK) moving up after reporting solid first quarter earnings...
If you thought biotech news was getting quiet going into earnings season, think again. Acadia Pharmaceuticals Inc. (ACAD) presents Phase II data on pimavanserin, a treatment  for Parkinson’s...
Amicus Therapeutics (NASDAQ: FOLD) had a late afternoon surge, up 7% to $10.73. The 52 week range is $9.00 to $18.22. Baxter International (NYSE: BAX)—contaminant in recalled Heparin identified by...
LucasArts and BioWare Corp. today announced that they have entered into an agreement to create an interactive entertainment product.  Normally we wouldn’t cover this because both are...
Goldman Sachs has one of the more premiere research shops for the bulge bracket firms on Wall Street and investors look to its "Conviction Buy List" with regularity.  It might not seem...
Electronic Arts Inc. (NASDAQ:ERTS) has announced what is roughly an $800 million diluted (before any long-term debt absorption) agreement with Elevation Partners to acquire VG Holding Corp., the...
Microsoft (NASDAQ:MSFT) is giving investors and the public a gift today.  The company has announced that Bungie Studios, the creators of Halo 3 and the Halo franchise, is going on the path to...